RankingsPricing
  1. US-listed companies
  2. NEUROCRINE BIOSCIENCES INC
  3. Financials
  4. Cash from financing

NEUROCRINE BIOSCIENCES INCNBIX

Market cap
$15.2B
P/E ratio
SummaryFinancials
Period EndCash from financing (Million USD)YoY (%)
Dec 31, 2024-487-845.33%
Dec 31, 202365-127.87%
Dec 31, 2022-234-955.11%
Dec 31, 202127-117.36%
Dec 31, 2020-158-677.75%
Dec 31, 201927-7.51%
Dec 31, 201830-94.28%
Dec 31, 2017517+21516.99%
Dec 31, 20162-99.14%
Dec 31, 2015277+99.66%
Dec 31, 2014139+2516.58%
Dec 31, 20135-93.67%
Dec 31, 201284+29166.43%
Dec 31, 20110

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)